Recombinant CDKN2A/p14ARF Monoklonale antilichamen

CDKN2A generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by CDKN2A, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. CDKN2A is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene.

CDKN2A/p14ARF

Q8N726

Human

Recombinant Human CDKN2A/p14ARF protein

CDKN; CDKN2; MLM; CDKN2A; p14ARF

1F15

Unconjugated

WB

Cell Biology; Epigenetics and Nuclear Signaling; Cancer

Protein A

0.2 mg/mL

WB 1:1000-5000

PBS, 50% glycerol, 0.05% Proclin 300, 0.05% protein protectant.

Ice bag

Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles.

https://789.bio/eb/4eHZR6TM

14 kDa

16 kDa

IgG, κ